Pharmacokinetics and intraocular pressure lowering effect of timolol preparations in rabbit eyes
- PMID: 8951683
- DOI: 10.1089/jop.1996.12.471
Pharmacokinetics and intraocular pressure lowering effect of timolol preparations in rabbit eyes
Abstract
Two timolol preparations, a gel and an eyedrop with a thickening agent, and one commercial eyedrop without a thickening agent, were studied in rabbits. After topical administration of these three preparations in rabbits, aqueous humor was withdrawn and the proteins removed from the samples by precipitation with acetonitrile. Timolol concentrations were determined directly by an HPLC method. The HPLC mobile phase was composed of methanol and 5 mM d-camphorsulfonic acid (in 1% acetic acid) with a ratio of 49:51 (v/v). A reversed phase C18 column was used to separate samples with a flow rate of 0.8 mL/min and a UV detector set at 284 nm. A two-compartment pharmacokinetic model was used to fit the aqueous humor level for determining the drainage (kd) and absorption rate constants (ka) in the precorneal area as well as the elimination rate constant (ke) of timolol in aqueous humor. For ka +kd, the eyedrop without a thickening agent had the highest value (0.160 min-1), followed by the eyedrop with a thickening agent (0.030 min-1), and the gel had the lowest value (0.009 min-1). It suggests that the gel has a longer retention time in eyes to improve ocular bioavailability and decrease side effects. The AUC0 approximately infinity for the aqueous humor profile with time coordinates were 4142, 2974, and 1604 micrograms min/mL, for the gel, the eyedrop with a thickening agent, and the eyedrop without a thickening agent, respectively. In another study, timolol preparations were also topically administered in alpha-chymotrypsin-induced glaucoma rabbits for determining the lowering effect on intraocular pressure (IOP). The durations of depressing IOP for the gel, the eyedrop with a thickening agent, and the eyedrop without a thickening agent were 24, 14 and 10 hrs, respectively. Thus, the gel preparation has a longer duration and a higher ocular bioavailability which might be further developed in the treatment of open-angle glaucoma.
Similar articles
-
Pharmacological evaluation of a new timolol/pilocarpine formulation.Ophthalmic Res. 1998;30(2):101-6. doi: 10.1159/000055461. Ophthalmic Res. 1998. PMID: 9523288
-
Bioavailability of timolol and aceclidine after ocular instillation in the rabbit.Res Commun Mol Pathol Pharmacol. 1998 Apr;100(1):35-42. Res Commun Mol Pathol Pharmacol. 1998. PMID: 9644717
-
Ocular pharmacokinetic/pharmacodynamic modeling for multiple anti-glaucoma drugs.Biol Pharm Bull. 2008 Aug;31(8):1590-5. doi: 10.1248/bpb.31.1590. Biol Pharm Bull. 2008. PMID: 18670094
-
Metabolism of ophthalmic timolol: new aspects of an old drug.Basic Clin Pharmacol Toxicol. 2011 May;108(5):297-303. doi: 10.1111/j.1742-7843.2011.00694.x. Basic Clin Pharmacol Toxicol. 2011. PMID: 21385322 Review.
-
The beta-adrenergic blocking agents and the treatment of glaucoma.Surv Ophthalmol. 1979 May-Jun;23(6):347-62. doi: 10.1016/0039-6257(79)90228-5. Surv Ophthalmol. 1979. PMID: 37605 Review.
Cited by
-
Sustained Delivery of Timolol Maleate for Over 90 Days by Subconjunctival Injection.J Ocul Pharmacol Ther. 2016 Dec;32(10):642-649. doi: 10.1089/jop.2016.0042. Epub 2016 Nov 11. J Ocul Pharmacol Ther. 2016. PMID: 27835065 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous